Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Westlake Aldringskohort (WeAC)

5. november 2026 oppdatert av: Westlake University

Westlake Aldringskohorten

The Westlake Ageing Cohort (WeAC) is a longitudinal cohort study conducted in Hangzhou, Zhejiang Province, China. The investigators aim to enroll 2,800 participants aged 55 years and older for long-term follow-up. The population will include individuals with neurodegenerative diseases or those at the prodromal stage of cognitive impairment, as well as healthy middle-aged and older adults serving as controls. The investigators will collect their sociodemographic, dietary, lifestyle, clinical, and neuroimaging data, as well as biological samples.

Studieoversikt

Detaljert beskrivelse

The investigators will recruit middle-aged and aged participants, including healthy controls and individuals with neurodegenerative disorders such as mild cognitive impairment (MCI), Alzheimer's disease (AD), Parkinson's disease dementia (PDD), and dementia with Lewy bodies (DLB), etc. The aim of this study is to construct a longitudinal database that includes sociodemographic, lifestyle, clinical, neuroimaging, and multi-omics data. This database will be used to characterize the molecular signatures of neurodegenerative disorders. In addition, the investigators will identify biomarkers associated with neurodegenerative diseases. Furthermore, the investigators aim to uncover the mechanisms underlying the progression of mild cognitive impairment (MCI) and other neurodegenerative disorders.

Studietype

Observasjonsmessig

Registrering (Antatt)

2800

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Zhejiang
      • Hangzhou, Zhejiang, Kina, 310058
        • Rekruttering
        • Hangzhou First People's Hospital
        • Ta kontakt med:
      • Hangzhou, Zhejiang, Kina, 310058
        • Rekruttering
        • Hangzhou Third People's Hospital
        • Ta kontakt med:
          • Peng Li, Master
        • Ta kontakt med:
          • Yu Chen, Master

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

55 år til 90 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

All participants must be Chinese residents, regardless of their ethnicity.

Beskrivelse

Inclusion Criteria:

  1. Age between 55 and 90 years (inclusive) at baseline.
  2. Availability of a companion capable of providing independent functional assessments and fluent in Chinese.
  3. Willingness and ability to regularly complete required surveys and physical examinations as per study protocol.
  4. MMSE scores were required to be 24-30 (inclusive) for healthy controls and MCI; and 20-24 (inclusive) for AD and DLB/PDD patients.
  5. Healthy controls: CDR = 0, memory box = 0. MCI: CDR = 0.5, memory box ≥ 0.5. AD: CDR = 0.5 or 1. The DLB/PDD meets the core features of diagnosis.
  6. Healthy controls exhibit no significant cognitive or functional decline. Patients with MCI have objective cognitive impairment not sufficient for an AD diagnosis. AD patients fulfill the NINCDS-ADRDA criteria. DLB/PDD patients meet their respective international consensus diagnostic criteria. Other neurodegenerative diseases meet the diagnostic criteria.

Exclusion Criteria:

  1. Participants with major medical or neuropsychiatric conditions unrelated to the study purposes were excluded. These included, but were not limited to, psychiatric disorders, cancer, infectious diseases, structural brain abnormalities, and epilepsy.
  2. Current use of psychoactive medications or any other drugs that may affect the study.
  3. Participants with cardiac pacemakers, artificial heart valves, or metallic implants in the eyes, skin, or any other part of the body.
  4. Participants with any other diseases that may affect the study.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Cognitive function
Tidsramme: 48 months

Cognitive function will be evaluated using the Mini-Mental State Examination (MMSE, score range: 0-30, with higher scores indicating better cognitive function) and clinical diagnosis provided by physicians.

48 months
Gut microbiome
Tidsramme: 48 months

The gut microbiome will be profiled by metagenomic sequencing or ITS rRNA sequencing. In addition, fecal microbiota will be cultured, isolated, and identified.

48 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Brain magnetic resonance imaging
Tidsramme: 48 months

Use brain magnetic resonance imaging (MRI) to measure the brain structure and function of participants.

48 months
Positron emission tomography
Tidsramme: 48 months

Assess the brain function and neurological disorders by positron emission tomography (PET).

48 months
Brain images relevant inspections
Tidsramme: 48 months

Other brain image relevant inspections required for study to measure brain structure and function of participants.

48 months
Electroencephalogram
Tidsramme: 48 months

Electroencephalogram (EEG) monitors the electrical activity of the brain. And further measure based on coupled EEG/MEG and eye-tracking.

48 months
Blood biochemical parameters
Tidsramme: 48 months

Blood biochemical parameters, including glucose and lipids, will be analyzed using an automated biochemical analyzer.

48 months
Serum inflammatory factors
Tidsramme: 48 months

Detect and assess serum inflammatory factors such as IL-1β, IL-6, and IL-12, in serum from participants.

48 months
Health and behavior monitoring
Tidsramme: 48 months

Use fitness trackers to record the physiological and behavioral data of participants.

48 months
Sleep data measurement
Tidsramme: 48 months

Use the polysomnography (PSG) to record the sleep data of participants to evaluate the sleep quality.

48 months
Continuous glucose monitoring
Tidsramme: 48 months

Use the continuous glucose monitoring (CGM) for dynamic blood glucose recording to determine the glycemic control of participants.

48 months
Environmental measurement
Tidsramme: 48 months

Use the environmental monitoring device to measure various exposure factors in the participants' living environment.

48 months
Multi-omics data
Tidsramme: 48 months

Multi omics results of detecting biological samples such as plasma, peripheral blood mononuclear cells (PBMCs), urine, feces, saliva, etc.

48 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Ju-Sheng Zheng, PhD, Westlake University

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

3. juni 2026

Primær fullføring (Antatt)

31. desember 2030

Studiet fullført (Antatt)

31. desember 2031

Datoer for studieregistrering

Først innsendt

24. desember 2025

Først innsendt som oppfylte QC-kriteriene

19. januar 2026

Først lagt ut (Faktiske)

28. januar 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

6. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

5. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 20251023ZJS001

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere